⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRMD News
CorMedix Inc.
Quantum Health Showcases Continued Innovation that Lowers the Total Cost of Care
businesswire.com
CRMD
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
globenewswire.com
CRMD
Mundipharma gibt positive vorläufige Ergebnisse der Phase-III-Studie ReSPECT bekannt, in der ▼ REZZAYO ® (Rezafungin) zur Prophylaxe invasiver Pilzerkrankungen nach einer allogenen hämatopoetischen Stammzelltransplantation untersucht wurde
businesswire.com
CRMD
Mundipharma宣布评估用于预防异基因造血干细胞移植患者侵袭性真菌病的 ▼ REZZAYO ® （雷扎芬净）的三期ReSPECT临床试验取得积极总体结果
businesswire.com
CRMD
Mundipharma anuncia resultados positivos preliminares del estudio de Fase III ReSPECT que evalúa ▼ REZZAYO ® (rezafungina) para la profilaxis de enfermedades fúngicas invasivas en pacientes sometidos a trasplante...
businesswire.com
CRMD
Mundipharma annonce les premiers résultats positifs de l’essai de phase III ReSPECT évaluant ▼ REZZAYO ® (rézafungine) dans la prophylaxie des infections fongiques invasives chez les patients ayant subi une greffe allogénique...
businesswire.com
CRMD
Mundipharma宣布，其評估 REZZAYO ® （雷扎芬淨）用於預防異基因造血幹細胞移植患者侵襲性真菌病的III期ReSPECT試驗取得正面頂線結果
businesswire.com
CRMD
Form 8-K
sec.gov
CRMD
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
businesswire.com
CRMD
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
globenewswire.com
CRMD